Categories

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia

Tercera dosis COVID-19 comenzará a aplicarse en centros de larga estancia3 de diciembre del 2021. La Comisión Nacional de Vacunación y Epidemiología (CNVE) aprobó que a partir del miércoles 8 de diciembre se proceda

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2224-tercera-dosis-covid-19-comenzara-a-aplicarse-en-centros-de-larga-estancia

 
Categories

Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 – Letter to Clinical Laboratory Staff and Health Care Providers

Laboratories should expect some false negative results because the SARS-CoV-2 virus can mutate over time and not be detected.

http://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2

 
Categories

Gilead Issues A Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates

Foster City, CA, Gilead Sciences Inc. (Nasdaq: GILD) today announced it is voluntarily recalling two lots of Veklury® (remdesivir 100 mg for injection) to the user level. Gilead Sciences Inc. received a customer complaint, confirmed by the firm’s investigation, of the presence of glass particulates.

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-two-lots-vekluryr-remdesivir-due-presence-glass

 
Categories

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injectio

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-one-lot-enoxaparin-sodium-injection-usp-40mg04-ml-due

 
Categories

August 7, 2019 UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality

The FDA is providing updated information about a late mortality signal in patients treated for peripheral artery disease (PAD) in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents. This communication updates the January 17 and March 15, 2019 notifications.

http://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel

 
Categories

Autoridades reafirman importancia de prevención y vacunación ante variante Ómicron

Autoridades reafirman importancia de prevención y vacunación ante variante Ómicron

Autoridades reafirman importancia de prevención y vacunación ante variante Ómicron30 de noviembre del 2021. Ante la aparición de la nueva variante COVID-19 nombrada Ómicron

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2220-autoridades-reafirman-importancia-de-prevencion-y-vacunacion-ante-variante-omicron